EP 1851244 A1 20071107 - AN ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATEMENT OF CANCER AND GLYCOSYLATION VARIANTS THEREOF
Title (en)
AN ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATEMENT OF CANCER AND GLYCOSYLATION VARIANTS THEREOF
Title (de)
ANTI-CD137-ANTIKÖRPER ALS MITTEL FÜR DIE BEHANDLUNG VON KREBS, UND GLYKOSYLIERUNGSVARIANTEN DAVON
Title (fr)
ANTICORPS ANTI-CD137 EN TANT QU'AGENT DANS LE TRAITEMENT DE CANCERS ET VARIANTE DE GLYCOSYLATION DUDIT ANTICORPS
Publication
Application
Priority
US 2005004739 W 20050215
Abstract (en)
[origin: WO2006088447A1] The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as an anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals.
IPC 8 full level
C07K 16/00 (2006.01); A61K 39/395 (2006.01); C12P 21/00 (2006.01)
CPC (source: EP)
C07K 16/2878 (2013.01); A61K 2039/507 (2013.01); C07K 2317/12 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2006088447 A1 20060824; EP 1851244 A1 20071107; EP 1851244 A4 20090415; EP 2399935 A2 20111228; EP 2399935 A3 20120222
DOCDB simple family (application)
US 2005004739 W 20050215; EP 05723079 A 20050215; EP 11173253 A 20050215